Hikma highlighted as "one to watch" in 2008
Hikma Pharmaceuticals, a Jordanian drugmaker listed in London, UK, has been selected as one of the top six stocks to watch by the Daily Telegraph's Simon Goodley in his City Diary Hot Gossip column. The firm's growth rate, which has seen it double in size every four years, is expected to continue as governments in key markets in the Middle East and North Africa focus on increasing health care spending.
Last month, Hikma forecast that it would achieve 40% revenue growth for the full year and organic growth, excluding the acquisitions of Ribosepharm, Thymoorgan and Alkan Pharma, of around 20%. Financial results for the year ended December 31, 2007, are due on March 12.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze